Product Information
ERYTHROMYCIN 200 MG/5 ML SUSP is a generic product labeled by Nivagen Pharmaceuticals Inc., priced at $0.9123 per ML under NDC 75834029501. Its NADAC has been published 173 times since Jun 14, 2023.
FDA first approved this application on Nov 21, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
200 mg/5mL
Manufacturer
Nivagen Pharmaceuticals Inc.NDC
75834029501
Classification
Generic
Dosage Form
SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ERYTHROMYCIN ETHYLSUCCINATEApproval Type
Generic (ANDA)
FDA Application
ANDA216212FDA Approved
11/21/2022
TE Code
AB
On Market Since
2/1/2023
Pharmacological Classes
Price Statistics
The NADAC for ERYTHROMYCIN 200 MG/5 ML SUSP has been published 173 times since Jun 14, 2023, and over the history we have for it it has declined 55.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.9123 per ML |
|---|---|
| All-time high | $2.0710 (Jun 14, 2023) |
| All-time low | $0.7325 (Apr 17, 2024) |
| 52-week high | $1.0408 |
| 52-week low | $0.7608 |
| Median price | $1.0753 |
| Average price | $1.1008 |
| Largest weekly change | -41.2% (Apr 17, 2024) |
| Weeks tracked | 173 |
| Tracking since | Jun 14, 2023 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Nivagen Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Erythromycin Ethylsuccinate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Macrolide Antimicrobial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ERYTHROMYCIN 200 MG/5 ML SUSP?
The current National Average Drug Acquisition Cost (NADAC) for ERYTHROMYCIN 200 MG/5 ML SUSP, manufactured by Nivagen Pharmaceuticals Inc., is $0.9123 per ML (NDC 75834029501), effective Sep 30, 2026.
How has the price of ERYTHROMYCIN 200 MG/5 ML SUSP changed over time?
Over the history we have for it, the NADAC for ERYTHROMYCIN 200 MG/5 ML SUSP has declined 55.9%. It has been tracked across 173 weekly CMS publications since Jun 14, 2023.
What are the highest and lowest recorded NADAC prices for ERYTHROMYCIN 200 MG/5 ML SUSP?
Since Jun 14, 2023, the NADAC for ERYTHROMYCIN 200 MG/5 ML SUSP has ranged from a low of $0.7325 (Apr 17, 2024) to a high of $2.0710 (Jun 14, 2023), with a median of $1.0753 per ML.
Are there cheaper alternatives to ERYTHROMYCIN 200 MG/5 ML SUSP?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as ERYTHROMYCIN 200 MG/5 ML SUSP in a comparable dosage form, but none are currently priced below it.
Who manufactures ERYTHROMYCIN 200 MG/5 ML SUSP?
ERYTHROMYCIN 200 MG/5 ML SUSP (NDC 75834029501) is labeled by Nivagen Pharmaceuticals Inc., and CMS classifies it as a generic product.